Top Story Today
ARPA-H Drops $160 Million to Turn Custom Gene Editing Into a Platform, Not a Luxury
Right now, personalized gene editing requires building each therapy from scratch and remains prohibitively expensive. ARPA-H wants to change that. Its new $160 million THRIVE program is funding seven teams to build reusable gene-editing platforms where the core machinery stays the same and only the targeting instructions change, like apps running on one operating system. The timeline is aggressive: patients dosed in first-in-human trials within three years. Perhaps more consequential, the program is working alongside the FDA to create an umbrella approval pathway for gene-editing platforms, which could slash the regulatory cost of adding new disease targets.
Why it matters: If THRIVE's platform model works, it could fundamentally rewire the economics of genetic medicine, turning gene editing from a bespoke luxury available to almost nobody into a scalable, deployable treatment model for thousands of rare diseases.
Read more →Outbreak & Pandemic Preparedness
The Ebola Strain Nobody Has a Vaccine For Just Infected an American
An American doctor in Congo tested positive for Bundibugyo ebolavirus, a strain with no approved vaccine or treatment and a fatality rate between 25% and 50%. The DRC outbreak has already hit 1,792 confirmed cases and 625 deaths. WHO has launched a clinical trial of Mapp Biopharmaceutical's MBP134 antibody cocktail in over 1,000 patients, while vaccine candidates from IAVI, Oxford, and Moderna race toward the clinic.
Read more →A Vaccine Skeptic Who'd 'Rather Perish' Than Vaccinate His Kids Is Nominated to Run U.S. Pandemic Response
Sean Kaufman, nominated for the ASPR role that coordinates America's emergency health playbook, has publicly expressed opposition to vaccines and refused to vaccinate his own children. The nomination follows HHS moves that already slashed routine childhood vaccine targets from 17 to 11 diseases, raising alarms across public health leadership.
Read more →Clinical & Regulatory
AstraZeneca's Gene-Silencing Drug Aced Every Biological Test and Still Failed
Eplontersen crushed TTR protein levels and improved imaging biomarkers in a 1,400-patient Phase 3 ATTR cardiomyopathy trial, then showed zero benefit on the endpoint that actually matters: keeping patients alive and out of the hospital. The culprit appears to be the stabilizer drugs most patients were already taking; in patients not on a stabilizer, the drug showed a 29% reduction in cardiovascular events. The result reshuffles a $5 billion market.
Read more →Corcept Gets Early FDA Approval for a Drug That Turns Cortisol Against Cancer
The FDA approved relacorilant (Lifyorli) more than three months ahead of schedule for platinum-resistant ovarian cancer. The first-in-class cortisol blocker extended median survival by four months in a disease where patients typically live about a year. No biomarker required, which gives it a broad patient population that targeted therapies can't reach.
Read more →FDA Slams the Door on Cheap Compounded GLP-1 Knockoffs
With semaglutide and tirzepatide shortages officially over, the FDA is dismantling the legal pathway for large-scale GLP-1 compounding, proposing to permanently ban these drugs from the 503B bulks list. The agency has sent over 55 warning letters to telehealth companies in 2026 alone and documented more than 1,700 adverse events tied to compounded versions.
Read more →Deals & Strategy
AstraZeneca Pays Up to $1.77 Billion to Crack RNA Delivery Beyond the Liver
Every approved siRNA drug today only works in the liver. AstraZeneca is betting up to $1.77 billion (just $30 million upfront) on Chinese pharma company CSPC's technology for delivering siRNA therapies to the kidneys. It's AstraZeneca's third major deal with CSPC, signaling real confidence in the platform's potential to unlock extrahepatic RNA medicine.
Read more →Ipsen Drops €700 Million on the Only Drug in Development for a Virus That Wrecks Transplanted Kidneys
BK polyomavirus causes viruria in up to 30–40% of kidney transplant recipients and leads to clinically significant nephropathy in 1–10%, and there is no approved targeted treatment. Ipsen is paying up to €700 million for Memo Therapeutics' antibody potravitug, which showed kidney tissue healing in Phase II despite missing its primary viral clearance endpoint. A pivotal Phase III trial is expected later this year.
Read more →Novo and Lilly Turn the GLP-1 Price War Into a Subscription Battle
Novo Nordisk launched Netflix-style Wegovy subscriptions at $249 per month for annual commitments, undercutting Lilly's lowest Zepbound price. Lilly fired back with cheaper single-dose vials through LillyDirect, starting at $299. Both companies are fighting for cash-pay patients whose insurance won't cover obesity drugs, borrowing pricing tactics straight from consumer tech.
Read more →